5α-reductase

5α-reductase-IN-1 is a potent inhibitor of the enzyme 5α-reductase. This compound is primarily employed in research studies to investigate its potential efficacy in treating patterned alopecia. It is commonly used in combination with minoxidil, a well-known treatment for hair loss.

5α-Reductase is the enzyme responsible for converting testosterone into 5-α dihydrotestosterone (DHT), a potent androgen involved in male sexual differentiation. The 5α-reductase family comprises three subfamilies and five isozyme members: 5αR1, 5αR2, 5αR3, GPSN2, and GPSN2L.

Aldose reductase-IN-5 is an inhibitor of aldose reductase (ALR2) that enhances the combination of inhibitory excitability and antioxidant capacity, thereby delaying the diabetes complications progress.

Epristeride (ONO-9302) is an orally active, selective and non-competitive steroidal 5-α-reductase isoform 2 inhibitor that inhibits SR isoform 2.Episteride reduces prostate size and improves symptoms in men with BPH.Episteride induces atrophy and apoptosis of the ventral prostate in rats.

Izonsteride (LY320236) is a selective and potent 5alpha reductase inhibitor with dual action on the type I and type II isoforms of the enzyme.Izonsteride is used in the treatment of oncology and genitourinary disorders, and may be used in the study of prostate cancer.

Lapisteride (CS-891) a steroidal 5α-reductase inhibitor is used to treat benign prostatic hyperplasia (BPH) and androgenetic alopecia and may be effective in preventing or treating AGA .

AS-601811 is a steroidal 5α-reductase inhibitor and androgen receptor modulator used to study hair loss and acne.

Turosteride is a small molecule steroidal 5α-reductase (5α-reductase) inhibitor.Turosteride has antitumor activity for the treatment of oncologic diseases and genitourinary disorders, and may be used in the study of prostate cancer.

Isomer-Turosteride (Isomer-Turosteride(Isomer-137099-09-3)) is a novel 5 alpha-reductase inhibitor.The antiprostatic effect of Isomer-Turosteride in adult rats is associated with the inhibition of the conversion of T to DHT.Isomer-Turosteride induces a decrease in prostate DHT independent of a secondary increase in T. Isomer-Turosteride has anticancer activity and inhibits the growth of tumor cells. Turosteride has anticancer activity and inhibits the growth of tumor cells. Translated with www.DeepL.com/Translator (free version)

Bexlosteride (LY300502), a benzoquinolinone derivative, functions as a human type I 5α-reductase inhibitor. It demonstrates metabolic inhibition, antiproliferative, and antisecretory activities specifically in LNCaP human prostatic adenocarcinoma cell cultures, positioning it as a potent agent for prostate cancer research [1] [2].

Finasteride (MK-906) is an oral inhibitor of active testosterone 5-alpha-reductase and Ki value is 10 nM.

Dutasteride (GI 198745) is a 5-alpha-reductase inhibitor that inhibits both type-1 and type2 isoforms of the enzyme and is used to treat benign prostatic hyperplasia.

Kopexil is a compound similar to minoxidil that promotes hair growth and treats hair loss by inhibiting 5α-reductase and possibly activating potassium channel switches, which improve hair follicles by prolonging the anagen phase of the hair growth cycle and improving.

Alpha-Estradiol (Epiestradiol) is an estrogen that inhibits 5alpha-reductase and has potential in the study of androgenetic alopecia.

SRD5A1-IN-1 is an inhibitor of steroid 5α-reductase type 1 (SRD5A1, IC50 = 1.44 µM). SRD5A1-IN-1 lowers the production of dihydrotestosterone and shows a significant decrease in the SRD5A1 protein expression.

CGP-53153 is a steroidal inhibitor of 5 alpha-reductase, with IC50 values of 36 nM in rat prostatic tissue and 262 nM in human prostatic tissue.

4-Androsten-3-one-5-ene-17-carboxylic acid is a derivative of progesterone and functions as a 5α-reductase inhibitor. It prevents the transformation of testosterone into dihydrotestosterone in homogenates of the rat ventral prostate.

NSC 224249 is an effective dual inhibitor of human CYP17A1 and 5α-reductase that effectively blocks the androgen synthesis pathway. It can be used to treat androgen-dependent diseases such as prostate cancer and for research into the regulation of steroid hormone metabolism.

SRD5A1-IN-2 is a steroid 5α-reductase type 1 (SRD5A1) inhibitor with an IC50 of 8.5 μM. It decreases the expression of the SRD5A1 protein in HaCaT cells and reduces the production of dihydrotestosterone (DHT) in these cells. This compound may be utilized in the study of androgen-related disorders such as androgenetic alopecia (AGA).

Finasteride (MK-906) acetate is a potent and competitive 5α-reductase inhibitor with an IC50 of 4.2 nM for type II 5α-reductase, demonstrating approximately 100-fold higher affinity for type II than type I. Finasteride acetate can be used for research on benign prostatic hyperplasia (BPH) and androgenic alopecia [1] [2] [3].

steroidal androgen receptor agonist

LY 191704 is a 5α-reductase type 1 inhibitor.

TF-505, a steroid 5α-reductase inhibitor, is used potentially for the treatment of benign prostatic hyperplasia.

4',7-Dimethoxyisoflavone (Daidzein dimethyl ether) , a kind of isoflavonoids, showed inhibitory effects on rat prostate testosterone 5α-reductase.